When 300 seconds are not the same: Platform- and cartridge-dependent variability of activated clotting time during left-sided ablation procedures
Year: 2026
Type: article
Abstract: Activated clotting time (ACT) is routinely used to guide unfractionated heparin administration during left-sided electrophysiology procedures, with current consensus recommendations targeting an ACT >300 seconds.1 However, commonly used ACT systems differ in reagents, detection methods, and calibration, while recommendations generally do not specify the measurement platform. Our previous international survey and systematic review demonstrated substantial heterogeneity in ACT platforms and anticoagulation strategies used in electrophysiology practice.
Source: Heart Rhythm
Authors: Valon Spahiu, Ivan Zeljkovic, Henning Nilius, Marianne Graf, Sophie Dütschler, Sime Manola, Berat Gerguri, Varis Gjergjizi, Arbnora Gerguri, Thomas Kueffer, Gregor Thalmann, Claudia Herrera-Siklody, Nikola Kozhuharov, Helge Servatius, Hildegard Tanner, Laurent Roten, Ana Jordan, Nikola Pavlovic, Michael Nagler, Tobias Reichlin, Boldizsar Kovacs
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Funders: National Science Foundation, Roche, Boston Scientific Corporation, Freiwillige Akademische Gesellschaft, European Commission, European Society of Cardiology, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Schweizerische Herzstiftung, Gottfried und Julia Bangerter-Rhyner-Stiftung, Daiichi Sankyo Europe
Awards: G3775098764, Derivation and External Validation of a Predictive Score for Right Ventricular Pacing Induced Cardiomyopathy Following AV Node Ablation, Heart Failure Outcomes in the Left Atrial Arrhythmia Substrate identification by Ultra High-Density Mapping after confirmed durABLE PV isolation - A randomised controlled pilot study.
OpenAlex ID: W7204530367